Upadacitinib Salvage Therapy for Infliximab experienced patients with Acute Severe Ulcerative Colitis.

Robert GilmoreLian TanRichard FernandesYoon-Kyo AnJakob Begun

Published in: Journal of Crohn's & colitis (2023)

Upadacitinib may have a role as a safe and effective salvage therapy for steroid-refractory ASUC in patients who have previously failed to respond to infliximab therapy. Prospective studies are required to determine the safety and efficacy of upadacitinib use in this setting before routine use can be recommended.

Keyphrases

ulcerative colitis
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
clinical practice
patient reported outcomes